Umeclidinium is a long-acting muscarinic antagonist (LAMA) used mainly for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It works by relaxing airway muscles and improving breathing. Umeclidinium was developed by GlaxoSmithKline and became available as part of inhalation therapies, including combination inhalers with vilanterol or fluticasone furoate. It was approved in the early 2010s and has since become widely used for long-term management of COPD due to its once-daily dosing and effective bronchodilator action.
Image
